- TLDR Biotech
- Archive
- Page 6
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | August 7 - 8, 2024
Eli Lilly's stupendous Q2 results, AI-biotechs Recursion & Exscientia merge, Vertex's Casgevy reaches reimbursement deal with UK's NHS, Novartis' FDA accelerated approval for nephropathy med, Bavarian Nordic snag $150M+ BARDA contract, Sanofi's Ph3 myeloma win, Merck & Co.'s Ph3 lung cancer miss, and Sarepta's earnings disappoint investors
Biotech & Pharma Updates | August 6 - 7, 2024
Novo Nordisk posts disappointing Q2 earnings, Chugai acquires Japan rights to Roche IBD med, Amgen's Horizon acquisition continues to pay off in Q2 earnings, IDRx's $120M Series B, Pharmacosmos buys G1 Therapeutics, Novo pulls back Wegovy heart failure submission, and insider trading doesn't pay
Biotech & Pharma Updates | August 5 - 6, 2024
Agios to collect a fat $1.1B milestone payment after FDA approval, Symbiotic Capital life science credit firm launches with $600M, Shinobi Therapeutics extends Series A + lands $59M grant, Pfizer invests in antimicrobial resistance, Merck & Co. signs T-cell engager bispecific partnership with Daiichi Sankyo, Bayer touts massive management cuts over H1 2024, BioMarin shrinks Roctavian gene therapy ambitions
Biotech & Pharma Updates | August 4 - 5, 2024
Bayer posts heart failure Ph3 win, Mallinckrodt sells Therakos division to PE firm at a substantial loss, MBX Biosciences $63.5M Series C, Actinium turns to partnership after FDA rejection, BioNTech posts $883M net loss for Q2, and gene therapy biotech Lacerta Therapeutics shuts down
Biotech & Pharma Updates | August 1 - 4, 2024
Vir in-licences three Sanofi T-cell engager clinical assets, Paragon Therapeutic's fourth opco launches with $80M, Vertex boosts 2024 outlook on Casgevy sales (and also cuts two rare disease Ph1 assets), Eli Lilly's Zepbound, Mounjaro no longer on US shortage list, Ribon Therapeutics shutters
Biotech & Pharma Updates | July 31 - August 1, 2024
Gene therapy legend James Wilson launches two new companies, Adaptimmune's engineered cell therapy for solid tumors gets historic accelerated approval, venBio closes fifth life science fun at $500M+, Sanofi commits $1.4B for new insulin manufacturing facility, uniQure decimates its workforce via 65% layoffs, and Novartis continues to fight FDA's Entresto generic approval
Biotech & Pharma Updates | July 30 - 31, 2024
J&J lands FDA approval for "foundational" multiple myeloma combo, Eisai drops more Leqembi data in support of long term use, Umoja cleared to dose first patients with their in situ CAR-T, AIRNA raises $60M Series A, Sanofi sues Sarepta over their DMD gene therapy, and EuroAPI is having a tough "transition year"
Biotech & Pharma Updates | July 29 - 30, 2024
BioNTech & Regeneron's mRNA cancer combo reports positive Ph2 data, Merck & Co. takes earnings hit after surprise Gardasil sales slowdown in China, Roche kicks off injectable GLP-1 Ph2 trial, Pfizer looks back on track with recent earnings report, and GLP-1s may help combat smoking
Biotech & Pharma Updates | July 28 - 29, 2024
GSK and Flagship sign 10 drug development partnership, Boehringer Ingelheim pays up to $1.3B for Nerio Therapeutics, Merck gets positive Keytruda opinion from CHMP, Spear Bio spears $45M Series A, Cognition Therapeutics handed Ph2 Alzheimer's L, and Pfizer lays off 200+ employees across two sites
Biotech & Pharma Updates | July 25 - 28, 2024
BMS' strong earnings bump stock up 10%, Dexcom stock drops 40% after lowering 2024 sales forecast, multiple big pharmas land EU adcomm thumbs up, while Biogen, Eisai's Leqembi for Alzheimer's gets a thumbs down from the same committee, and Confo Therapeutics raises $65M for small molecule & antibody drug discovery
Biotech & Pharma Updates | July 24 - 25, 2024
Pfizer lands EU approval for their hemophilia B gene therapy, a bunch of big pharmas report earnings, Chevron Doctrine might be resurrected, Ipsen buys pediatric cancer ex-US rights from Day One Biopharmaceuticals, while Roche, AbbVie, and Sanofi all clear out some of their clinical assets
Biotech & Pharma Updates | July 23 - 24, 2024
Pfizer's hemophilia A gene therapy posts positive Ph3, Novo Nordisk's Wegovy gets MHRA approval for a new indication, Gilead unveils full dataset for 100% efficacy HIV prevention shot, highway to funding with Autobahn's $100M Series C, FDA expresses doubt about AstraZeneca's lung cancer med prior to adcomm, and Novo Nordisk has their fourth fire of the year